Bioliberty secures £6.2 million Series A for rehabilitation technology
Scottish National Investment Bank led the financing with a £3 million investment to support product development and US expansion.
Bioliberty has secured £6.2 million in Series A funding, led by £3 million from Scottish National Investment Bank. Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC and Conduit Connect also participated.
The Edinburgh and Boston company develops robotic rehabilitation systems that help therapists deliver intensive treatment and track functional recovery. The investment supports new computer vision and care coordination capabilities, manufacturing in Scotland and expansion in the United States.
Bioliberty also plans to extend its Lifehub technology into patients’ homes. The Series A follows a separate £1.5 million pre-Series A financing in 2025.
Use of funds
Develop computer vision and care coordination capabilities in Lifehub Clinic
Support US commercialization and development of Lifehub Home